CME Group (CME) director receives 645-share fully vested stock grant

Rhea-AI Filing Summary

Durkin Bryan T reported acquisition or exercise transactions in this Form 4 filing.

CME Group Inc. director Bryan T. Durkin received an equity award of 645 shares of Class A Common Stock at $225.00 per share. The shares were granted as part of CME Group’s annual equity compensation program for non-employee directors and are fully vested with no further vesting conditions. Following this grant, Durkin directly holds 43,652 Class A shares.

Insights

Equity compensation analyst

Routine fully vested director stock grant with modest size relative to existing holdings.

The transaction is an A-code grant, meaning Bryan T. Durkin received 645 Class A shares as a stock award, not through an open-market purchase. The stated price of $225.00 per share reflects the valuation used for the grant rather than cash paid by the director.

The footnote clarifies this is part of CME Group’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan and that the shares are fully vested. After the award, Durkin directly owns 43,652 shares, indicating this is a relatively small, routine compensation-related addition rather than a major position change.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Durkin Bryan T

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Class A	645	$225.00	$145K

Holdings After Transaction: Common Stock Class A — 43,652 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity grant size: 645 shares Grant valuation price: $225.00 per share Post-grant holdings: 43,652 shares

3 metrics

Equity grant size 645 shares Class A Common Stock award to Bryan T. Durkin

Grant valuation price $225.00 per share Reported transaction price for the stock grant

Post-grant holdings 43,652 shares Total Class A shares directly held after the transaction

Key Terms

annual equity compensation program, CME Group Director Stock Plan, fully vested shares, non-employee directors

4 terms

annual equity compensation program financial

"issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors"

CME Group Director Stock Plan financial

"for non-employee directors under the CME Group Director Stock Plan"

fully vested shares financial

"Represents a grant of fully vested shares of Class A Common Stock"

non-employee directors financial

"annual equity compensation program for non-employee directors"

Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:14 PM Accepted by SEC EDGAR 06/29/2026 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Durkin Bryan T

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2026		A(1)		645	A	$225	43,652	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.

Remarks:

	/s/ Elizabeth Hensen, as Attorney-in-Fact for Bryan T. Durkin	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CME (CME) director Bryan T. Durkin report in this Form 4?

Bryan T. Durkin reported receiving 645 shares of CME Group Class A Common Stock. The shares were granted as part of the company’s annual equity compensation program for non-employee directors, rather than bought on the open market, and are fully vested upon grant.

Was the CME (CME) insider transaction a purchase or an equity grant?

The transaction was an equity grant, not a market purchase. It is coded “A” for grant or award, reflecting 645 Class A shares issued to Bryan T. Durkin as director compensation under the CME Group Director Stock Plan at a valuation of $225.00 per share.

Are the 645 CME Group shares granted to Bryan Durkin subject to vesting?

No. The footnote states the 645 Class A shares are fully vested and not subject to any vesting conditions. They were issued under CME Group’s annual equity compensation program for non-employee directors, meaning Durkin has full rights to the shares immediately upon grant.

How many CME (CME) shares does Bryan Durkin hold after this Form 4 transaction?

After the grant, Bryan T. Durkin directly holds 43,652 shares of CME Group Class A Common Stock. This total includes the newly granted 645 fully vested shares, giving investors a clear view of his current direct equity exposure as a non-employee director.

What was the reported price per share for Bryan Durkin’s CME equity grant?

The Form 4 reports a price of $225.00 per share for the 645-share grant. This figure typically reflects the grant’s fair value for compensation purposes, not an amount Durkin paid in cash, since the shares were awarded as part of CME’s director stock compensation program.